Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference
August 04 2021 - 7:30AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for serious rare and ultra-rare genetic diseases, today
announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief
Executive Officer and President will participate in a panel titled
Miss Con-GENE-iality - Updates in Gene Tx on Wednesday, August 11,
2021 at the Wedbush PacGrow Healthcare Conference at 12:00 PM ET.
The live and archived webcast of the presentation will be
accessible from the company’s website at
http://ir.ultragenyx.com/events.cfm. The replay of the webcast will
be available for 90 days.
About Ultragenyx Pharmaceutical Inc.Ultragenyx
is a biopharmaceutical company committed to bringing novel products
to patients for the treatment of serious rare and ultra-rare
genetic diseases. The company has built a diverse portfolio of
approved therapies and product candidates aimed at addressing
diseases with high unmet medical need and clear biology for
treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.Investors &
MediaJoshua Higa415-475-6370
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2024 to May 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From May 2023 to May 2024